Raymond James raised the firm’s price target on Adma Biologics (ADMA) to $32 from $25 and keeps a Strong Buy rating on the shares. Adma’s Q1 missed slightly from a non-recurring event and higher spend, but all the fundamentals are trending positively and 2025-2026 guidance was raised still with a lot of room for upside, the analyst tells investors in a research note. The firm adds that tariffs are “not an issue” for Adma.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- ADMA Biologics Reports Strong Q1 2025 Financial Growth
- ADMA Biologics Announces $500M Share Repurchase Program
- Adma Biologics options imply 10.9% move in share price post-earnings
- ADMA Biologics Inc (ADMA) Q1 Earnings Cheat Sheet
- Amazon sellers pull away from Prime Day, IBM to invest in U.S.: Morning Buzz